MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology (NYSE American: MAIA) reported initial Phase 2 THIO-101 Part C data in third-line advanced NSCLC. Ateganosine followed by cemiplimab (Libtayo) produced a 90.5% disease control rate (19/21) in 3L patients, compared with 25-35% for standard chemotherapy. MAIA said safety is acceptable and enrollment is completed internationally.
How this was made
The 30-second read
Why it matters
The disclosed 90.5% interim disease control rate in a more heavily pre-treated population is a fresh efficacy datapoint that can shift expectations for the program’s primary endpoint (ORR) and future trial/regulatory planning.
Market read
Traders can reassess MAIA’s near-term biotech risk profile based on a concrete interim efficacy readout in a defined, resistant 3L NSCLC cohort.
What to watch
Open-label design, small sample size (21 patients), interim scan timing, and the absence of safety details beyond “acceptable” could temper follow-through if subsequent endpoints disappoint.
Background
MAIA’s THIO-101 Phase 2 expansion Part C evaluates ateganosine followed by cemiplimab (Libtayo) as third-line therapy in advanced NSCLC after prior docetaxel and resistance to immunotherapy and other chemotherapies.
Ticker impact
MAIA reported Phase 2 THIO-101 Part C interim efficacy for ateganosine plus cemiplimab, with 90.5% DCR (19/21) in 3L NSCLC.
Likely positive near-term bias, with volatility around follow-up endpoints (ORR, durability) and safety updates.
The release provides specific interim efficacy numbers and a clear regimen (ateganosine followed by cemiplimab) in a defined expansion cohort, which is actionable for biotech traders. However, it is interim, open-label, and does not include ORR, duration, or statistical context.
Market effects
Supports the broader immuno-oncology/telomere-targeting narrative and may increase attention to sequencing strategies with PD-(L)1 inhibitors in resistant NSCLC.
Limited direct regional spillover; primarily impacts US microcap biotech sentiment.
Modest global relevance as the trial is described as international enrollment completed, but no cross-border regulatory or partnership decision is disclosed.
Counterpoint
A high disease control rate can mask limited tumor shrinkage; without ORR, PFS/DoR, and response durability, the market may over-discount the signal.
Key entities
- companyMAIA Biotechnology, Inc.
Clinical-stage biopharmaceutical company developing ateganosine (THIO) for NSCLC.
- clinical_programTHIO-101
Phase 2 trial evaluating ateganosine followed by PD-(L)1 inhibition, with Part C expansion in 3L NSCLC.
- drug_candidateateganosine (THIO)
Telomere-targeting investigational agent intended to prime immune responses before cemiplimab.
- drugcemiplimab (Libtayo)
PD-(L)1 inhibitor used after ateganosine in the THIO-101 regimen.
